127 related articles for article (PubMed ID: 27198909)
21. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?
Osazuwa-Peters N
Vaccine; 2013 Nov; 31(47):5500-5. PubMed ID: 24095883
[TBL] [Abstract][Full Text] [Related]
22. The ethics of implementing human papillomavirus vaccination in developed countries.
Malmqvist E; Helgesson G; Lehtinen J; Natunen K; Lehtinen M
Med Health Care Philos; 2011 Feb; 14(1):19-27. PubMed ID: 20853152
[TBL] [Abstract][Full Text] [Related]
23. Ethical issues related to human papillomavirus vaccination programs: an example from Bangladesh.
Salwa M; Abdullah Al-Munim T
BMC Med Ethics; 2018 Jun; 19(Suppl 1):39. PubMed ID: 29945621
[TBL] [Abstract][Full Text] [Related]
24. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
25. HPV Vaccinations in Lublin Region, Poland.
Kalinowski P; Grządziel A
Postepy Hig Med Dosw (Online); 2017 Feb; 71(0):92-97. PubMed ID: 28258669
[TBL] [Abstract][Full Text] [Related]
26. Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.
Drolet M; Deeks SL; Kliewer E; Musto G; Lambert P; Brisson M
Vaccine; 2016 Apr; 34(16):1874-80. PubMed ID: 26954465
[TBL] [Abstract][Full Text] [Related]
27. HPV vaccination in head and neck HPV-related pathologies.
Wierzbicka M; Józefiak A; Jackowska J; Szydłowski J; Goździcka-Józefiak A
Otolaryngol Pol; 2014; 68(4):157-73. PubMed ID: 24981297
[TBL] [Abstract][Full Text] [Related]
28. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs.
Duval B; Gilca V; McNeil S; Dobson S; Money D; Gemmill IM; Sauvageau C; Lavoie F; Ouakki M
Vaccine; 2007 Nov; 25(45):7841-7. PubMed ID: 17923173
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
30. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis.
Malagón T; Joumier V; Boily MC; Van de Velde N; Drolet M; Brisson M
Vaccine; 2013 Mar; 31(13):1740-7. PubMed ID: 23384753
[TBL] [Abstract][Full Text] [Related]
31. Preparing for HPV vaccination in South Africa: key challenges and opinions.
Harries J; Moodley J; Barone MA; Mall S; Sinanovic E
Vaccine; 2009 Jan; 27(1):38-44. PubMed ID: 18977271
[TBL] [Abstract][Full Text] [Related]
32. Human Papillomavirus Infection and Vaccination.
Valentino K; Poronsky CB
J Pediatr Nurs; 2016; 31(2):e155-66. PubMed ID: 26586310
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations.
World Health Organization. Electronic address: sageexecsec@who.int
Vaccine; 2017 Oct; 35(43):5753-5755. PubMed ID: 28596091
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and predictors of human papillomavirus vaccination in adolescent girls.
Palli SR; Mehta S; Aparasu RR
J Am Pharm Assoc (2003); 2012; 52(1):52-8. PubMed ID: 22257616
[TBL] [Abstract][Full Text] [Related]
35. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
36. Increasing HPV vaccination through policy for public health benefit.
Brandt HM; Pierce JY; Crary A
Hum Vaccin Immunother; 2016 Jun; 12(6):1623-5. PubMed ID: 26669416
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
38. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
[TBL] [Abstract][Full Text] [Related]
39. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
